Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide naturally secreted by the thymus gland and a master regulator of immune function. It is one of the most clinically validated immunomodulatory peptides in existence, with decades of research across infectious disease, oncology, and immunodeficiency.
Tα1 acts primarily by activating dendritic cells and T-helper cells (Th1 polarization), upregulating MHC class I and II expression, stimulating natural killer (NK) cell activity, and increasing the production of critical cytokines including IL-2, IFN-α, IFN-γ, and TNF-α. The net effect is a normalized, amplified adaptive immune response—not a nonspecific stimulation, but a targeted enhancement of the body’s ability to identify and clear pathogens and aberrant cells.
Thymosin Alpha-1 is FDA-approved in several countries as Zadaxin for hepatitis B and C, and has been studied in clinical trials for cancer, sepsis, HIV, and chronic infections. Research in immunocompromised populations consistently shows improved T-cell counts, reduced infection rates, and enhanced response to vaccines and chemotherapy.
For research use only.